ArticleTherapeutic advances in medical oncology2017
Myxofibrosarcoma primary cultures: molecular and pharmacological profile.
Article in Therapeutic advances in medical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges.Drug design, development and therapy · 2026Review
- Unveiling the myxofibrosarcoma tumor microenvironment: implications for immunotherapy.Frontiers in immunology · 2025Review
- Establishment and characterization of the novel myxofibrosarcoma cell line, SMU-MFS.Human cell · 2024Article
- A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models.BMC cancer · 2023Article
- Review
- Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.International journal of molecular sciences · 2023Article
- Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.Journal of personalized medicine · 2022Review
- Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture.Molecular oncology · 2022Article
- The emerging role of cancer nanotechnology in the panorama of sarcoma.Frontiers in bioengineering and biotechnology · 2022Review
- Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.Therapeutic advances in medical oncology · 2022Review
- Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas.International journal of molecular sciences · 2021Article
- Establishment and Characterization of a Cell Line (S-RMS1) Derived from an Infantile Spindle Cell Rhabdomyosarcoma withInternational journal of molecular sciences · 2021Article
- The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models.Journal of experimental & clinical cancer research : CR · 2021Article
- Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.Scientific reports · 2021Article
- Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy.Frontiers in oncology · 2021Article
- Epithelioid Sarcoma-From Genetics to Clinical Practice.Cancers · 2020Review
- Article
- Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies.Frontiers in oncology · 2020Review
- Multiple primary malignant neoplasms: A case report and literature review.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyxofibrosarcoma (MFS), formerly considered as a myxoid variant of malignant fibrous histiocytoma, is the most common sarcoma of the extremities in adults and is characterized by a high frequency of local recurrence. The clinical behavior of MFS is unpredictable and the efficacy of chemotherapy is still not well documented. Furthermore, given the relatively recent recognition of MFS as a distinct pathologic entity its cellular and molecular biology has still not been extensively studied in patient-derived preclinical models. We examined the molecular biology and treatment outcomes of high-grade, patient-derived MFS primary cultures.
methodsA total of three patient-derived MFS primary cultures were analyzed. We evaluated the role of CD109 expression and also looked for a correlation between transforming growth factor-beta (TGF-β) expression and sensitivity of the primary cultures to different drugs.
resultsCD109 was a promising marker for the identification of more aggressive high-grade MFS and a potential therapeutic target. The results also highlighted the potential role of TGF-β in chemoresistance. Pharmacological analysis confirmed the sensitivity of the cultures to chemotherapy. The most active treatments were epirubicin alone and epirubicin in combination with ifosfamide, the latter representing the current standard of care for soft tissue sarcomas (STSs), including MFS.
conclusionsOur results provide a starting point for further research aimed at improving the management of MFS patients undergoing chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.